Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma

Cancer

Volumn 104, Issue 8, 2005, Pages 1668-1677

  Kojima, Hiroshi ^a   Shijubo, Noriharu ^b   Yamada, Gen ^c   Ichimiya, Shingo ^c   Abe, Shosaku ^c   Satoh, Masaaki ^c   Sato, Noriyuki ^c  

^a Obihiro Kyokai Hospital   (Japan)

^b Sapporo General Hospital of Hokkaido Railway Company   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Mast cell density; Microvessel density; Nonsmall cell lung carcinoma; Prognosis; Vascular endothelial growth factor

Indexed keywords

CD34 ANTIGEN; CD68 ANTIGEN; TRYPTASE; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD34; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SERINE ENDOPEPTIDASES; SURVIVAL RATE; TRYPTASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 26444487268     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21366     Document Type: Article

References (38)

1. Ellis L, Fidler I. Angiogenesis and metastasis. Eur J Cancer. 1996;32A:2451-2460.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
5. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19:5598-5605.
6. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA. 1996;93:1988-1992.
7. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.
8. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flkl) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95:548-553.
9. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188:96-109.
10. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423-1425.
11. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20:1223-1231.
12. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1998;5:14389-14394.
13. Witzenbichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 1998;153:381-394.
14. Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA. 1999;96:9671-9676.
15. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101:1364-1374.
16. Maeda K, Yashiro M, Nishihara T, et al. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg Today. 2003;33:736-739.
17. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor-C and its receptors in non-small cell lung cancer. Br J Cancer. 2001;85:255-260.
18. Li Q, Dong X, Gu W, Qiu X, Wang E. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J. 2003;116:727-730.
19. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000;119:804-813.
20. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457-464.
21. Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer. 2004;91:498-503.
22. Nakashima T, Huang CL, Liu D, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit. 2004;10:BR157-BR165.
23. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6:2431-2439.
24. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9:1361-1369.
25. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res. 2004;10:5137-5144.
26. Bando H, Brokelmann M, Toi M, et al. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer. 2004;111:184-191.
27. Niki T, Iba S, Yamada T, Matsuno Y, Enholm B, Hirohashi S. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma. J Pathol. 2001;193:450-457.
28. Chen F, Takenaka K, Ogawa E, et al. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res. 2004;10:8548-8553.
29. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer. 2002;94:1083-1093.
30. Nagata M, Shijubo N, Walls AF, Ichimiya S, Abe S, Sato N. Chymase-positive mast cells in small sized adenocarcinoma of the lung. Virchows Arch. 2003;443:565-573.
31. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer. 2003;98:1217-1222.
32. Su JL, Shin JY, Yen ML, et al. Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res, 2004;64:554-564.
33. Shijubo N, Kojima H, Nagata M, et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech, 2003;60:186-198.
34. Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J. 2000;15:1087-1093.
35. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res. 1999;5:2506-2510.
36. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
37. Bono P, Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
38. Reis-Filho JS, Schmitt FC. Lymphangiogenesis in tumors: what do we know? Microsc Res Tech. 2003;60:171-180.